Know Cancer

forgot password

Open-label, Uncontrolled, Multi-center, Phase II Study of Cetuximab in Combination With mFOLFOX-6 as First-line Treatment in Patients With KRAS Wild-type, Unresectable LIver Metastases of colorEctal Cancer

Phase 2
18 Years
75 Years
Open (Enrolling)
Colorectal Cancer, Liver Metastases

Thank you

Trial Information

Open-label, Uncontrolled, Multi-center, Phase II Study of Cetuximab in Combination With mFOLFOX-6 as First-line Treatment in Patients With KRAS Wild-type, Unresectable LIver Metastases of colorEctal Cancer

During the last decade, chemotherapy in metastatic colorectal cancer (mCRC) has made
considerable progress.However, approximately 25% of patients with colorectal cancer present
with overt metastatic disease. In selected patients, synchronous or metachronous liver
metastases (LM) can be resected in curative intention. Over the last 5 years there has been
the recognition that preoperative, neoadjuvant, combination chemotherapy regimens, namely,
5-fluorouracil/folinic acid (5-FU/FA) in combination with either irinotecan or oxaliplatin
can facilitate to downsize the initially unresectable LM and make the resection possible.
The addition of targeted therapies might render them even more effective.

Due to these results, the investigators hypothesize that cetuximab in combination with
mFOLFOX6 as treatment in patients with KRAS wild-type, unresectable liver metastases of mCRC
may further improve clinical outcomes.

Inclusion Criteria:

- Male or female 18-75 years of age

- Performance status (ECOG) 0~1

- Unresectable, histologically confirmed, synchronous or metachronous liver metastasis
of colorectal cancer. Unresectable liver metastases is defined as:

- patients with five and more liver metastases and/or

- Liver metastases that are technically unresectable immediately, and expected
remaining functional liver tissue ≥ 30% after resection. (Patients should be
evaluated by a multidisciplinary team of three local surgeons and one local
radiologist, including surgical consultation for potentially resectable
patients on the basis of remaining liver volume, infiltration of all liver
veins, infiltration of both liver arteries, both portal branches or both bile

- Tumor tissue (primary or metastasis) genotypologically classified as KRAS wild-type
in codon 12 and codon 13 of the KRAS gene exon 2

- No prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)

- Presence of at least one index lesion of hepatic metastasis measurable by CT scan or
MRI, not in an irradiated area

- Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 8 g/dL

- Bilirubin level ≤ 1.0 x ULN

- AST and ALT < 1.5 x ULN

- Serum creatinine ≤ 1.0 x ULN

- Life expectancy of ≥ 3 months

- Male or female of child-bearing period should have effective contraception

- Signed written informed consent

Exclusion Criteria:

- Any investigational agent(s) within 4 weeks prior to entry

- Previous exposure to EGFR-targeting therapy

- Any evidence of extrahepatic metastases and/or primary tumor recurrence

- Total volumes of liver lesions > 70%

- Clinically relevant peripheral neuropathy

- Acute or sub-acute intestinal obstruction or history of inflammatory bowel disease

- Breast-feeding or pregnant women, no effective contraception if risk of conception
exists (for male and female patients up to 4 months after end of chemotherapy)

- Previous malignancy (except colorectal cancer, history of basal cell carcinoma of
skin or pre-invasive carcinoma of the cervix with adequate treatment)

- Known drug abuse/ alcohol abuse

- Known dihydropyrimidine dehydrogenase (DPD) deficiency

- Severe organ failures or diseases, including: clinically relevant coronary disease,
cardiovascular disorder or myocardial infarction within 12 months before study entry,
severe psychiatric illness, severe infection and DIC

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Resection rate (R0)

Outcome Time Frame:

from the first cycle of treatment (day one) to two month after the last cycle

Safety Issue:


Principal Investigator

Sanjun Cai, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fudan University


China: Ethics Committee

Study ID:

EMR 62202-203



Start Date:

December 2010

Completion Date:

December 2013

Related Keywords:

  • Colorectal Cancer
  • Liver Metastases
  • cetuximab
  • colorectal carcinoma
  • Colorectal Neoplasms
  • Neoplasm Metastasis
  • Liver Neoplasms